Valneva SE (WBO:VLA) ROIC %: -39.47% (As of Mar. 2026)


WBO:VLA Valneva SE WBO:VLA
56 GF Score
Price €2.24
GF Value €2.46
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Valneva SE ROIC %?

Valneva SE WBO:VLA +0.63% 56 ROIC % is -39.47% as of Mar. 2026. GuruFocus rates WBO:VLA with a GF Score™ of 56/100 and a GF Value™ of €2.46 (Fairly Valued). The stock has 6 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Valneva SE's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -39.47%.

As of today (2026-06-29), Valneva SE's WACC % is 20.21%. Valneva SE's ROIC % is -37.83% (calculated using TTM income statement data). Valneva SE earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Valneva SE  (WBO:VLA) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Valneva SE's WACC % is 20.21%. Valneva SE's ROIC % is -37.83% (calculated using TTM income statement data). Valneva SE earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Valneva SE ROIC % Related Terms


Valneva SE ROIC % Historical Data

* Premium members only.

The historical data trend for Valneva SE's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valneva SE ROIC % Chart

Valneva SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.32 -23.57 -22.41 -26.19 -29.91

Valneva SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.40 -15.13 -53.97 -40.24 -39.47

WBO:VLA vs VRTX, REGN, ALNY: ROIC % Comparison

For the Biotechnology subindustry, Valneva SE's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's ROIC % distribution charts can be found below:

* The bar in red indicates where Valneva SE's ROIC % falls into.


WBO:VLA
56GF Score
Valneva SE WBO:VLA
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valneva SE ROIC % Calculation

Valneva SE's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-81.631 * ( 1 - 0% )/( (288.148 + 257.732)/ 2 )
=-81.631/272.94
=-29.91 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=500.032 - 43.614 - ( 168.27 - max(0, 114.579 - 299.012+168.27))
=288.148

Valneva SE's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-94.784 * ( 1 - 0% )/( (257.732 + 222.582)/ 2 )
=-94.784/240.157
=-39.47 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=372.013 - 44.166 - ( 105.265 - max(0, 94.218 - 201.439+105.265))
=222.582

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -39.47% mean?
Valneva SE (WBO:VLA) has a ROIC % of -39.47% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Valneva SE and its competitors.
Is Valneva SE's ROIC % too high?
Valneva SE's current ROIC % is -39.47%. Overall, Valneva SE has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's ROIC % compare to VRTX and REGN?
Valneva SE's ROIC % of -39.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Valneva SE and its competitors. Valneva SE's current ROIC % is -39.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (WBO:VLA) is currently considered Fairly Valued. The stock's GF Value™ is €2.46, compared to a current price of €2.24 — trading 8.8% below its estimated fair value. The current ROIC % is -39.47%. Valneva SE's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Valneva SE (WBO:VLA), the current ROIC % is -39.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valneva SE (WBO:VLA) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued. The current stock price of €2.24 is trading 8.8% below its estimated GF Value™ of €2.46. GuruFocus considers Valneva SE to be Fairly Valued.

Key valuation signals for WBO:VLA:

  • ROIC %: -39.47%
  • GF Value™: €2.46 vs. price of €2.24 (8.8% below fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the WBO:VLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
56GF Score

Get the complete analysis for WBO:VLA

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.24
Price
€2.46
GF Value